Abstract
Colorectal cancer is a leading cause of cancer-related deaths worldwide. Novel drugs have been approved for the treatment of chemo-refractory metastatic colorectal cancer (mCRC) patients, however, despite their clinical approval, the success rates are highly variable. RENCA Macrobeads (RMBs), a form of biological-systems based therapy for the treatment of mCRC has been tested in a clinical trial setting. RMBs adapt to the cancerous environments through the regulation of biochemical pathways and the release of anti-neoplastic factors leading to a positive therapeutic response and improved survival in mCRC patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
